Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Real-world assessment of off-label direct oral anticoagulant dosing for venous thromboembolism.

Saunders JA, Gustafson WL, Vazquez SR, Jones AE, Witt DM.

J Thromb Thrombolysis. 2019 Oct;48(3):506-510. doi: 10.1007/s11239-019-01904-y.

PMID:
31230262
2.

Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.

Marik PE, Cavallazzi R.

PLoS One. 2015 Nov 20;10(11):e0143252. doi: 10.1371/journal.pone.0143252. eCollection 2015. Review.

3.

Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment.

Tran E, Duckett A, Fisher S, Bohm N.

J Thromb Thrombolysis. 2017 May;43(4):505-513. doi: 10.1007/s11239-017-1487-z.

PMID:
28271315
4.

Comparison of Prescribing Practices with Direct Acting Oral Anticoagulant Protocols.

Draper E, Parkhurst B, Carley B, Krueger K, Larson T, Griesbach S.

Am J Cardiovasc Drugs. 2017 Dec;17(6):475-479. doi: 10.1007/s40256-017-0243-2.

PMID:
28887621
5.

Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens.

Trujillo-Santos J, Di Micco P, Dentali F, Douketis J, Díaz-Peromingo JA, Núñez MJ, Cañas I, Mastroiacovo D, Saraiva de Sousa M, Monreal M; RIETE Investigators.

Thromb Haemost. 2017 Jan 26;117(2):382-389. doi: 10.1160/TH16-07-0494. Epub 2016 Oct 27.

PMID:
27786333
6.

The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry.

Bauersachs R, Agnelli G, Gitt AK, Monreal M, Mismetti P, Willich SN, Laeis P, Fronk EM, Bramlage P, Cohen AT; PREFER in VTE Scientific Steering Committee.

Thromb Res. 2017 Sep;157:181-188. doi: 10.1016/j.thromres.2017.07.029. Epub 2017 Jul 28.

PMID:
28780343
7.

Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.

Wu C, Alotaibi GS, Alsaleh K, Linkins LA, McMurtry MS.

Thromb Res. 2015 Feb;135(2):243-8. doi: 10.1016/j.thromres.2014.10.033. Epub 2014 Dec 2.

PMID:
25488466
8.

Anticoagulation prescribing patterns in patients with cancer.

Xiang E, Ahuja T, Raco V, Cirrone F, Green D, Papadopoulos J.

J Thromb Thrombolysis. 2018 Jan;45(1):89-98. doi: 10.1007/s11239-017-1558-1.

PMID:
29052104
9.

Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease.

Shaw J, de Wit C, Le Gal G, Carrier M.

J Thromb Haemost. 2017 May;15(5):925-930. doi: 10.1111/jth.13670. Epub 2017 Apr 3.

10.

[Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].

Sunaga T, Shimizu T, Nakamura S, Takahashi N, Higashino M, Matsui M, Hozumi T, Ebato M, Suzuki H, Kogo M, Watanabe T, Sasaki T.

Yakugaku Zasshi. 2019;139(3):461-467. doi: 10.1248/yakushi.18-00026. Japanese.

11.

Evaluation of anticoagulation selection for acute venous thromboembolism.

Badreldin H, Nichols H, Rimsans J, Carter D.

J Thromb Thrombolysis. 2017 Jan;43(1):74-78. doi: 10.1007/s11239-016-1417-5.

PMID:
27592341
12.

Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation - Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration.

Suwa M, Morii I, Kino M.

Circ J. 2019 Apr 25;83(5):991-999. doi: 10.1253/circj.CJ-18-1282. Epub 2019 Mar 27.

13.

OC-13 - Safe and effective use of direct oral anticoagulants (DOAC) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism.

Ross JA, Miller M, Hernandez CR.

Thromb Res. 2016 Apr;140 Suppl 1:S173-4. doi: 10.1016/S0049-3848(16)30130-X. Epub 2016 Apr 8.

PMID:
27161685
14.

Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis.

Vasanthamohan L, Boonyawat K, Chai-Adisaksopha C, Crowther M.

J Thromb Haemost. 2018 Jul;16(7):1288-1295. doi: 10.1111/jth.14156. Epub 2018 Jun 17.

PMID:
29772108
15.

Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran.

Leung TS, Law EH.

Drug Des Devel Ther. 2015 Jul 9;9:3557-69. doi: 10.2147/DDDT.S70299. eCollection 2015. Review.

16.

Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.

Rollins BM, Silva MA, Donovan JL, Kanaan AO.

Clin Ther. 2014 Oct 1;36(10):1454-64.e3. doi: 10.1016/j.clinthera.2014.06.033. Epub 2014 Aug 3.

PMID:
25092394
17.

Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.

Janczak DT, Mimier MK, McBane RD, Kamath PS, Simmons BS, Bott-Kitslaar DM, Lenz CJ, Vargas ER, Hodge DO, Wysokinski WE.

Mayo Clin Proc. 2018 Jan;93(1):40-47. doi: 10.1016/j.mayocp.2017.10.007. Epub 2017 Dec 6.

PMID:
29217335
18.
19.

Is it reasonable to use a lower DOAC dose in some patients with VTE? NO.

Dentali F, Fantoni C.

Intern Emerg Med. 2017 Aug;12(5):565-567. doi: 10.1007/s11739-017-1695-8. Epub 2017 Jun 27.

PMID:
28656545
20.

Dosing Accuracy of Direct Oral Anticoagulants in an Academic Medical Center.

Schwartz J, Merrill S, de Leon N, Thompson A, Fang M.

J Hosp Med. 2017 Jul;12(7):544-550. doi: 10.12788/jhm.2769.

Supplemental Content

Support Center